Third Quarter 2023 Financial Results and Business Update Conference Call

Patrick Holt
President & CEO

Tom Reilly
CFO



November 1, 2023

Forward Looking Statements & Disclaimer

This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (VAZKEPA® in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, generic product launches, research and development, intellectual property and litigation matters, and other statements and beliefs that are forward-looking in nature and depend upon or refer to future events or conditions, including certain financial initiatives, metrics, and guidance.

These statements involve known and unknown risks, uncertainties and other factors that can cause actual results to differ materially. Investors should not place undue reliance on forward-looking statements, which speak only as of the presentation date of this presentation. Please refer to the "Risk Factors" section in Amarin's most recent Forms 10-K and 10-Q filed with the SEC and cautionary statements outlined in recent press releases for more complete descriptions of risks in an investment in Amarin.

THIS PRESENTATION IS INTENDED FOR COMMUNICATION WITH INVESTORS AND NOT FOR DRUG PROMOTION.

Today's Agenda

01

Third Quarter 2023 Business Update
Patrick Holt, President & CEO

02

Third Quarter 2023 Financial Results
Tom Reilly, CFO

03

Looking Ahead to the Remainder of 2023 & 2024
Patrick Holt, President & CEO

01

THIRD QUARTER 2023 BUSINESS UPDATE

Patrick Holt, President & CEO

FOCUS ON OPERATIONAL MOMENTUM

EUROPE
Accelerate European Revenue and P&R Outcomes

U.S.
Extend Product Lifecycle and Drive Profit

RoW
Maximize Patient Uptake via Partnerships

CONTINUE CASH PRESERVATION

EUROPE: NEW LEADERSHIP DRIVING EARLY COMMERCIAL & ONGOING PRICING & REIMBURSEMENT PROGRESS

European Commercial Updates

UK (England, Wales & Scotland)	Double-digit growth in demand from England/Wales; Ongoing access to formularies in Scotland.
Spain	Promising initial sales across regions; Commercial team focused on early adopters.
Netherlands	Promising initial sales. Commercial strategy focused on key accounts identified by extensive market research.

European Pricing & Reimbursements Completed

- England and Wales
- Finland
- Sweden
- Netherlands
- Scotland
- Austria*
- Denmark*
- Switzerland*
- Spain

Ongoing EU Pricing & Reimbursement Efforts

- France
- Italy
- Germany
- Austria
- Norway
- Portugal
- Switzerland
- Belgium

*Individual Reimbursement.

U.S.: THREE YEARS POST-GENERIC, BRANDED VASCEPA REMAINS MARKET LEADER DRIVING PROFIT



Despite Three Years of Generic Competition, U.S. Business has maintained

57%

MARKET SHARE

ROW: PARTNERS ARE BRINGING VASCEPA/VAZKEPA TO MORE PATIENTS GLOBALLY



- Launched
- Regulatory Approval Achieved
- Regulatory Preparations Underway

Canada
Launched in February 2020
HLS Therapeutics Inc.

Israel (Neopharm)
Approved March 2023
NEOPHARM

China
Launched in October 2023 (VHTG)
EDDING PHARM

Hong Kong
Approved February 2022
EDDING PHARM

South Korea and ASEAN (Lotus)
Approval Processes Ongoing
Lotus

MENA
Launched in Lebanon (2018), UAE (2019), Qatar (2022), Kuwait (2023), KSA (2023)
Biologix FZCO

Australia / New Zealand
Australia Approved November 2022,
New Zealand Approved January 2023
CSL Seqirus

20+ Regulatory Processes Underway

Note: The company is pursuing expansion into these various additional markets and the status of regulatory and/or patent approval will vary market to market.

02 THIRD QUARTER 2023 FINANCIAL RESULTS AND 2023 GUIDANCE

Tom Reilly, CFO

MANAGING OPERATING EXPENSES TO MAXIMIZE PROFITABILITY AMID REVENUE PRESSURE





U.S. Revenue Remained Flat Despite Generic Market

- 3Q 2023 total net revenues remained flat at **$66 million vs Q2 '23** [(1)]
- 3Q 2023 European net product revenues were **$0.8 million**

Key Operating Expense Drivers:

- Q3' 23 $51M compared to Q2' 23 $57M
- On track to deliver $40M Opex reduction by July 2024

*Excludes Q2 '23 $14M licensing revenue, of which $11M is non-cash, related to a change in accounting estimate
(1) Includes $6.5M one-time Medicaid rebate adjustment

CONTINUED FOCUS ON CONTROLLING COSTS AND MAXIMIZING CASH



Third Quarter 2023

Cash Positive ~$8M

- Cash balance at 9/30/2023 approximately $321M; $15M+ versus Q3 2022
- Expense reductions and timely EUR investments based on pricing and reimbursement decisions
- Continued progress renegotiating supply purchase agreements - process ongoing
- Received $5M Employer Retention Credit from the IRS

* Excludes one-time supply restructuring payment of $25M
** Excludes one-time supply restructuring payment of $10M

03 LOOKING AHEAD TO THE REMAINDER OF 2023 & EARLY 2024

Patrick Holt, President & CEO

FOCUS ON OPERATIONAL MOMENTUM

EUROPE
Accelerate European Revenue and P&R Outcomes

U.S.
Extend Product Lifecycle and Drive Profit

RoW
Maximize Patient Uptake via Partnerships

CONTINUE CASH PRESERVATION

Q&A

Vascepa® (icosapent ethyl) Vazkepa® (icosapent ethyl)

THANK YOU

AMARIN®